Micro-Raman spectroscopy, integrated with statistical analysis, discriminates CLL prognostic groups, revealing biochemical heterogeneity beyond conventional molecular markers. The method identifies ...

Longitudinal data reveal consistent initial responsiveness to targeted agents but limited durability once patients cycle through both BTKi and BCL2i classes.

Expert Rev Hematol. 2013;6(4):441-449. The newest biological variables of prognostic relevance are useful for understanding the clinical heterogeneity of disease, however, their value at the time of ...

As therapy for chronic lymphocytic leukemia (CLL) continues to evolve, 2025 brought research, regulatory news, and expert ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. I think this is one of the most exciting ...

Jim Plotkin shares his personal experience with CLL, including his initial symptoms, the diagnostic process, challenges faced, and advice for patients with newly diagnosed CLL. Medical experts discuss ...

Here are the top 5 articles detailing the advancements in hematologic oncology from 2025. BTK inhibitors have revolutionized ...

Follicular lymphoma is a chronic, incurable blood cancer requiring regular monitoring, even during remission. Blood work is routine, but CT scans can trigger anxiety due to their role in initial ...

The Haslam 3 Foundation has donated $2 million to Pelotonia, supporting their mission of fighting cancer. The donation, led by Dee and Jimmy Haslam, will specifically support research on Chronic ...